Emergency PWAS in Respiratory Infectious Disease
A legfontosabb adatok
- Ki végzi
- The University of Hong Kong
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 2000 fő, tervezett
- Kezdés
- 2023. ápr. 11.
- Várható befejezés
- 2028. máj. 1.
- A vizsgálat típusa
- Megfigyeléses, 7 csoport
- A vizsgált kezelések
- Biomarker blood draw and saliva collection
- A regiszteradat frissítve
- 2026. május 12.
Ki vehet részt
- Életkor
- 18 év – 100 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 26 feltétel megnézéseKevesebb
Ki vehet részt
- Patients eligible for enrolment include:
- With reference to previous inclusion criteria are:
- Adults ≥18 years of age; AND
- Suspected, acute, community-acquired, respiratory, infectious disease (scaRID)*; AND
- Informed consent; Note: scaRID is defined according to ALL three criteria:
- Community acquired (not hospitalised for <28 days); AND
- Acute infection (defined as symptom onset <8 days and any ONE of reported fever or chills or aural temperature >37.5°C or hypothermia or leucocytosis or leucopaenia or new altered mental status); AND
- Probable respiratory infection - According to any ONE of:; new cough or new sputum production or; chest pain or; dyspnoea or; tachypnoea or; abnormal lung examination or; respiratory failure; or; physician's judgment (presenting with systemic or gastrointestinal symptoms); Control subjects will be drawn from two groups:
- The worried well - adult patients with a National Early Warning Score (NEWS) <3 and a temperature <37.5°C
- Relatives or accompanying friends with no acute illness
Ki nem vehet részt
- Solid organ or haematopoietic stem-cell transplant within the previous 90 days
- Skin or orthopaedic infections
- Urinary tract infection
- Sexual transmitted disease
- Human immunodeficiency virus (HIV) infection
- Active graft-versus-host disease or bronchiolitis obliterans
- Severe traveller's disease requiring urgent hospitalisation and management including malaria, dengue, typhoid and other rickettsial diseases
- Stroke
- Refusal of consent
- Recent hospitalisation (<28 days)
- Enrolled in another clinical trial
- Cellulitis
- Acute abdominal sepsis
- Immunocompromised/potential neutropenic fever
- Toxidrome
- Non-organic acute psychosis
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 100 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Kína.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Develop an emergency PanorOmics Wide Association Study (ePWAS) for the early, rapid biological and pathophysiological characterisation of known and novel Infectious Diseases in adult patients presenting to emergency departments with suspected, acute, community-acquired respiratory infectious disease (scaRID).
A teljes eredeti leírásKevesebb
Phase 1
1. Develop an ED-ID biobank (named ePWAS-RID). Phase 2 2. Targeted research for the discovery of novel diagnostics, prognostics and therapeutics
A vizsgálat 7 csoportja
- Viral infection
Viral infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree
Kezelés: Biomarker blood draw and saliva collection
- Bacterial infection
Bacterial infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
Kezelés: Biomarker blood draw and saliva collection
- Viral-Viral co-infection
Viral-viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
Kezelés: Biomarker blood draw and saliva collection
- Bacterial-Viral co-infection
Bacterial-Viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
Kezelés: Biomarker blood draw and saliva collection
- Fungal-Mycobacterium co-infection
Bacterial-Viral co-infection subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
Kezelés: Biomarker blood draw and saliva collection
- Infection of uncertain origin
Infection of uncertain origin subjects presenting within 8 days from symptom onset will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms; and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if available); and c) 48 hours +/- 6 hours from symptom onset (if available).
Kezelés: Biomarker blood draw and saliva collection
- Control Subjects
Control group subjects, if they agree, will have at least one whole blood and saliva drawn a) in the emergency department (if available) or hospital within 8 days of the onset of symptoms (if applicable); and if they agree, a further two samples at b) 24 hours +/- 6 hours from symptom onset (if applicable); and c) 48 hours +/- 6 hours from symptom onset (if applicable).
Kezelés: Biomarker blood draw and saliva collection
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Emergency PanorOmic Wide Association Study in Respiratory Infectious Disease (ePWAS-RID)
- Kérdések a feltételekről
- Forrás: NCT05336851: ki vehet részt
- A regiszteradat frissítve
- 2026. május 12.